Relmada Therapeutics (RLMD) Change in Cash (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Change in Cash data on file, last reported at $6.3 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 331.96% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $8.6 million, a 4755.23% increase from a year earlier, with the FY2025 full-year figure at -$360486.0, down 53.7% from the prior year.
• Change in Cash for Q1 2026 stood at $6.3 million, up from $2.1 million in the prior quarter.
• Over the last five years, Change in Cash for RLMD reached as high as $23.5 million in Q1 2023 and fell as low as -$37.1 million in Q4 2022.
• Historically, Change in Cash has averaged -$2.0 million across 5 years, with a median of $31133.0 in 2025.
• Across the five-year window, Change in Cash plunged 986.8% in 2022 and surged 4686.45% in 2023, its largest moves.
• Year by year, Change in Cash stood at -$37.1 million in 2022, then jumped by 92.98% to -$2.6 million in 2023, then jumped by 191.03% to $2.4 million in 2024, then declined by 11.01% to $2.1 million in 2025, then soared by 197.33% to $6.3 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $6.3 million in Q1 2026, $2.1 million in Q4 2025, and $31133.0 in Q3 2025.